Argus Reiterates Buy Rating on Moderna (MRNA), 'Discounted price offers buying opportunity'
Tweet Send to a Friend
Argus analyst John Eade reiterated a Buy rating and $180.00 price target on Moderna (NASDAQ: MRNA).The analyst comments "We are ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
